All News
The RheumNow Week in Review -30 March 2018
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.
Read Article
The RheumNow Week in Review - 23 March 2018
Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.
Read Article
Repeat Malignancy Unlikely with Biologic Therapy
Research from the Danish biologics registry shows that the use of a biologic in patients with a history of a primary cancer does not increase the risk of a second malignant neoplasm (SMN) or mortality in rheumatoid arthritis (RA) patients.
Read Article
Opportunistic Infections in RA Rare with Biologics
The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis has studied nearly 20,000 patients and observed that there is no substantially different risk of opportunistic infections between different biologics.
Read Article
The RheumNow Week in Review - 9 March 2018
Dr. Jack Cush reviews highlights, news and recent research published this past week on RheumNow.com. This week's report includes news on new regulatory changes, new indication for tofacitinib, the rise and deficits of opioids and the benefits of fish and bariatric surgery.
Read Article
FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis
Yesterday a FDA advisory panel voted 15-0 in favor of approving Xeljanz (tofacitinib) 10 mg bid for patients with moderate to severe ulcerative colitis.
Read Article
Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept
The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T
Read Article
The RheumNow Week in Review - 2 March 2018
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.
Read Article
2017 Rheumatology Year in Review
This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017. In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.
Read Article
The RheumNow Week in Review - 23 February 2018
Dr Jack Cush reviews highlights from the past week on RheumNow.com. This week’s video is in two parts; for part Ii, go to https://buff.ly/2BM9MjL
Read Article
Pediatric Use of TNF inhbitors Does Not Increase Malignancy Risk
A study of USA administrative claims data between 2000 to 2014 assessed the risk of cancer with exposure to tumour necrosis factor inhibitor (TNFi) in pediatric patients and found that TNFi therapy did not significantly increase the risk compared those not receiving TNFi.
Read Article
RWCS Day 4 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui, with excerpts from leading teachers in rheumatology. This podcast features presentations from Drs.
Read Article
The RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read Article
RWCS Day 2 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui with excerpts from leading teachers in rheumatology. This podcast features Drs. Martin Bergman, Jack Cush, Rachel Tate, Phil Aleksiejuk, Shubha Kollampare, Orrin Troum, and Alvin Wells. Listen here or on Stitcher, iTune, iPhone, Soundcloud or Google play.
Read Article
RWCS Meeting Begins Today
The 11th annual meeting of the Rheumatology Winter Clinical Symposium (RWCS) begins today (2/7) and runs through Saturday (2/10) and features a premiere faculty delivering state-of-the-art lectures.
Read Article
Biosimilar Reports - February 2018
Biosimilars command a great deal of research, development and attention given the promise of significant cost savings and potentially wider use for those in need. The global biosimilar market is expected to reach $36 billion USD by 2022. Here is this month's roundup of clinical trials and journal articles, overviews/reviews, practice and physician attitudes, and regulatory and pharma news - all on the subject of biosimilars.
Read Article
Less Cardiovascular Risk with Abatacept in Rheumatoid Arthritis
A claims data analysis shows that abatacept use in rheumatoid arthritis (RA) patients yielded a modestly reduced cardiovascular risk when compared to patients receiving TNF inhibitors (TNFi).
Read Article
The RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read Article
Obesity Outweighs Psoriasis in Comorbidity Risk with Children
Like their adult counterparts, psoriasis in children is an independent risk factor for comorbidity, but not as much as obesity.
Read Article
Anti-Drug Antibodies Partly Explain Secondary TNF Inhibitor Failures
An observational study of patients with active rheumatoid arthritis (RA) or spondyloarthritis (SpA) experiencing secondary failure to TNF inhibitor (TNFi) therapy showed that (secondary) loss of efficacy to a TNFi was associated with anti-drug antibodies in less than 30% of patients.
Read Article
